pf-00217830
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00580125)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine D2 receptorAGONIST
DRD2 agonist
- Dopamine D2 receptorPARTIAL AGONIST
Dopamine D2 receptor partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C1CCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)nc2N1- Mol. weight
- 430.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1774080 ↗
Also known as
- 3,4-dihydro-7-(4-(1-naphthalenyl)-1-piperazinyl)butoxy-1,8-naphthyridin-2(1h)-one
- pf00217830
- pf 00217830
- pf-00217830
- pf-00217830
- pf-00217830
- pf-00217830
- pf-217830
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00580125 | Phase 2 | Nov 1, 2007 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1